Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

Inclusion Criteria: * Patient with biopsy confirmed sarcoidosis meeting American Thoracic Society criteria 23 * Patient on \>5 mg prednisone for pulmonary indications * FVC \<85% predicted * Prednisone dose not reduced in prior 3 months * Deterioration of pulmonary disease over the past year * Decrease in FVC \>5% * Age: 18 through 90 (i.e., candidates must have had their 18th birthday, but not had their 91st birthday). Exclusion Criteria: adrenal insufficiency (Addison's disease) * Scleroderma * a fungal infection * herpes infection of the eyes * osteoporosis * a stomach ulcer * congestive heart failure * high blood pressure * recent surgery * if you are allergic to pork proteins * Do not receive a smallpox vaccine or any "live" vaccine while you are using corticotropin. * Patients receiving anti-Tumor Necrosis Factor antibody (e.g. infliximab, adalimumab) in prior six months * Uncontrolled diabetes, hypertension, or other contra-indication to increased dosage of glucocorticoids * Patients requiring therapy for pulmonary hypertension * Females of childbearing potential who are known to be pregnant and/or lactating or who have a positive urine pregnancy test on screening. * Current participation in another research drug treatment protocol (patient cannot start another experimental agent until after 90 days) * Any other condition that the investigator feels would pose a significant hazard to the patient if Acthar Gel therapy is initiated.